Honasa calls off proposed Fluence Pharma acquisition over unmet closing conditions

Honasa, the parent company of Mamaearth, has decided not to go through with its planned acquisition of Fluence Pharma. This decision comes after the company was unable to meet certain conditions required for the deal to be completed. The proposed acquisition was announced in June and would have given Honasa a 58 percent stake in Fluence Pharma for an enterprise value of Rs 135 crore. This development may impact the company's plans for expansion in the nutraceuticals sector.

Why it matters

The acquisition was proposed but not completed. This news does not affect the overall market sentiment.

Market impact

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Moneycontrol. For information only — not financial advice.